Skip to main content

Table 2 Mean tumour marker levels during fulvestrant treatment

From: Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment

Patient response mean marker levels (+/- SD) (month)
  1 2 3 4 5 6 7 8 9
     P-values (1→4 months) P-values (1→6 months)   
PR (n = 7)
   CA 15-3 144.00 128.54 156.87 178.16 170.19 197.01    
   (kU/l) +/-171.75 +/-164.90 +/-194.54 +/-227.42 +/-256.43 +/-270.54    
     N.S.   N.S.    
   CEA 5.31 4.17 3.87 3.81 3.46 4.06    
   (μg/l) +/-3.96 +/-2.82 +/-2.61 +/-2.54 +/-2.78 +/-2.95    
     N.S.   0.0165    
SD ≥ 6 months (n = 28)
   CA 15-3 184.68 214.00 226.54 240.64 269.05 268.61    
   (kU/l) /-214.08 +/-262.54 +/-297.58 +/-305.39 +/-352.19 +/-338.27    
     0.0023   < 0.0001    
   CEA 52.59 43.63 43.49 58.01 55.28 72.70    
   (μg/l) +/-201.99 +/-153.74 +/-153.73 +/-224.58 +/-203.94 +/-307.61    
     N.S.   0.0399    
SD ≥ 6 < 9 months (n = 14)
   CA 15-3 205.21 232.21 265.50 281.07 302.71 309.04    
   (kU/l) +/-256.19 +/-309.81 +/-378.08 +/-378.57 +/-424.97 +/-429.82    
     0.0017   0.0002    
SD ≥ 9 months (n = 14)
   CA 15-3 164.14 195.79 185.57 200.21 214.50 229.07 209.55 258.61 263.29
   (kU/l) +/-169.24 +/-215.55 +/-194.18 +/-216.47 +/-229.92 +/-263.48 +/-226.84 +/-283.62 +/-292.21
     0.0405   0.0146    
De novo PD (n = 32)
   CA 15-3 259.91 419.41 441.16 580.31      
   (kU/l) +/-419.29 +/-994.42 +/-790.95 +/-1052.69      
     < 0.0001      
   CEA 140.61 192.37 199.98 250.09      
   (μg/l) +/-652.01 +/-902.53 +/-907.67 +/-1087.32      
     0.0002      
Secondary PD (n = 28)
   CA 15-3 411.20a 510.67b 572.50c 698.72d      
   (kU/l) +/-541.50 +/-834.03 +/-891.17 +/-1164.36      
     < 0.0001      
   CEA 56.32 a 53.46 b 69.99 b 110.32 d      
   (μg/l) +/-224.80 +/-203.92 +/-269.53 +/-473.03      
     < 0.0001      
  1. PR, partial response; SD, stable disease; PD, disease progression; NS, not statistically significant; a2 months before PD; b1 months before PD; cPD; d1 month after PD